Ultragenyx Pharmaceutical (RARE) Short-term Investments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Short-term Investments data on file, last reported at $238.0 million in Q1 2026.

• Quarterly Short-term Investments fell 35.22% year-over-year to $238.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $238.0 million (down 35.22% YoY) and the FY2025 annual result came in at $259.0 million, down 40.6% from the prior year.
• Short-term Investments fell to $238.0 million in Q1 2026 per RARE's latest filing, from $259.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $614.8 million in Q4 2022 and bottomed at $222.7 million in Q3 2025.
• The 5-year median for Short-term Investments is $369.5 million (2023), against an average of $385.5 million.
• The widest annual swing landed in 2022, when Short-term Investments soared 42.12%; it then slumped 52.71% in 2025.
• Tracing RARE's Short-term Investments over 5 years: stood at $614.8 million in 2022, then plunged by 40.86% to $363.6 million in 2023, then climbed by 19.9% to $436.0 million in 2024, then plunged by 40.6% to $259.0 million in 2025, then declined by 8.11% to $238.0 million in 2026.
• Per Business Quant, the three latest RARE Short-term Investments figures stand at $238.0 million (Q1 2026), $259.0 million (Q4 2025), and $222.7 million (Q3 2025).

Peer Comparison